Circulating Procollagen Type III N-Terminal Peptide and Mortality Risk in African Americans With Heart Failure.

Autor: Mansour IN; Department of Medicine, University of Illinois at Chicago, Chicago, Illinois., Bress AP; Department of Pharmacy Practice, University of Illinois at Chicago, Chicago, Illinois., Groo V; Department of Medicine, University of Illinois at Chicago, Chicago, Illinois; Department of Pharmacy Practice, University of Illinois at Chicago, Chicago, Illinois., Ismail S; Department of Medicine, University of Illinois at Chicago, Chicago, Illinois., Wu G; Department of Medicine, University of Illinois at Chicago, Chicago, Illinois., Patel SR; Department of Pharmacy Practice, University of Illinois at Chicago, Chicago, Illinois., Duarte JD; Department of Pharmacy Practice, University of Illinois at Chicago, Chicago, Illinois., Kittles RA; Department of Medicine, University of Illinois at Chicago, Chicago, Illinois., Stamos TD; Department of Medicine, University of Illinois at Chicago, Chicago, Illinois., Cavallari LH; Department of Pharmacy Practice, University of Illinois at Chicago, Chicago, Illinois. Electronic address: lcavallari@cop.ufl.edu.
Jazyk: angličtina
Zdroj: Journal of cardiac failure [J Card Fail] 2016 Sep; Vol. 22 (9), pp. 692-9. Date of Electronic Publication: 2015 Dec 22.
DOI: 10.1016/j.cardfail.2015.12.016
Abstrakt: Background: Procollagen type III N-terminal peptide (PIIINP) is a biomarker of cardiac fibrosis that is associated with heart failure prognosis in whites. Its prognostic significance in African Americans is unknown. We sought to determine whether PIIINP is associated with outcomes in African Americans with heart failure.
Methods and Results: Blood was collected from 138 African Americans with heart failure for determining PIIINP and genetic ancestry, and patients were followed prospectively for death or hospitalization for heart failure. PIIINP was inversely correlated with West African ancestry (R(2) = 0.061; P = .010). PIIINP > 4.88 ng/mL was associated with all-cause mortality on univariate (hazard ratio [HR] 4.9, 95% confidence interval [CI] 2.2-11.0; P < .001) and multivariate (HR 5.8; 95% CI 1.9-17.3; P = .002) analyses over a median follow-up period of 3 years. We also observed an increased risk for the combined outcome of all-cause mortality or hospitalization for heart failure with PIIINP > 4.88 ng/mL on univariate (HR 2.6, 95% CI 1.6-5.0; P < .001) and multivariate (HR 2.4, 95% CI 1.2-4.7; P = .016) analyses.
Conclusions: High circulating PIIINP is associated with poor outcomes in African Americans with chronic heart failure, suggesting that PIIINP may be useful in identifying African Americans who may benefit from additional therapy to combat fibrosis as a means of improving prognosis.
Competing Interests: None of the authors have any conflict of interest to report.
(Copyright © 2015 Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: